UCL now has access to the Wiley-Blackwell Oncology and Hematology backfile collection, which comprises the older content of ... amp; Neck) Vol. 1, 1978-Hematological Oncology Vol. 1, 1983-International Journal of ... Apheresis Vol. 1, 1982-Journal of Surgical Oncology Vol. 1, 1969-Molecular Carcinogenesis Vol. 1, 1988-Medical and Pediatric Oncology (currently known as Pediatric Blood and Cancer) Vol. 1, ...

... US Oncology Physician Services, an ANCO Corporate Member.The Oncology Today meeting takes place on October 25th and ... 6.5 ACPE Contact HoursRegistration, course, and meals are freeJoin Oncology Today™ for the third annual accredited conference for community-based oncology ... research data and practical management issues in community oncology: • New drugs utilized to treat hematologic disorders and solid ...

SNM and the American Society for Therapeutic Radiation and Oncology (ASTRO) will cosponsor a symposium this fall examining the impact of translational advances on radiation oncology and cancer imaging. The two-day meeting, which takes place October 17-18, will bring together some of the world's leading experts and young investigators in the emerging field of molecular [...]

Peter Suber has posted an item (Open Access News, August 18, 2008) about Oncology Journals: Open-Access Publications, from Oncology Watch. It's a list of oncology journals that provide free access to full-text articles. Of the 21 journals on the list, I could identify only 7 for which an Impact Factor (IF) was available via the [...]

Medelis, an oncology contract research organization, has published a free abstract, "Preclinical Trials: A Nuanced Approach to Get Into the Clinic Faster." In ... abstract, Dr. Mike McGarry, a preclinical research scientist with 35 years of experience, discusses how oncology preclinical studies are commonly viewed as straightforward investigations run exclusively by researchers who operate without ...

... the big pharmas to exploit new concepts and rush new drug candidates to their pipelines. Nearly half of all drugs that are expected to enter the clinic in the coming years will be aimed at the oncology market. Consequently, early stage drug development for cancer is going to be the most active area in the industry, with an abundance of investment opportunities, particularly in small and medium ...